Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Andrew Kligerman | TD Cowen | 15 questions · 13% challenging |
| Wes Carmichael | Wells Fargo | 13 questions · 15% challenging |
| Jimmy Bhullar | JPMorgan | 13 questions · 31% challenging |
| Wilma Burdis | Raymond James | 13 questions · 8% challenging |
| Jack Matten | BMO Capital Markets | 12 questions · 17% challenging |
| Suneet Kamath | Jefferies | 11 questions · 9% challenging |
| Tom Gallagher | Evercore ISI | 10 questions · 10% challenging |
| Elyse Greenspan | Wells Fargo | 9 questions · 0% challenging |
| John Barnidge | Piper Sandler | 9 questions · 0% challenging |
| Ryan Krueger | KBW | 7 questions · 29% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wells Fargo | 2 analysts | 22 questions · 9% challenging |
| JPMorgan | 2 analysts | 17 questions · 24% challenging |
| TD Cowen | 1 analyst | 15 questions · 13% challenging |
| Raymond James | 1 analyst | 13 questions · 8% challenging |
| BMO Capital Markets | 1 analyst | 12 questions · 17% challenging |
| Jefferies | 1 analyst | 11 questions · 9% challenging |
| Evercore ISI | 1 analyst | 10 questions · 10% challenging |
| Piper Sandler | 1 analyst | 9 questions · 0% challenging |
Revenue grew 5.4% with operating EPS of $3.43, up 12%, as Globe Life articulated an AI strategy for enterprise-wide margin expansion. United American Medicare Supplement sales continued explosive growth, and mortality trends sustained the earnings improvement trajectory. Management raised FY2026 guidance from $14.95-$15.65 to $15.40-$15.90, driven by accelerated buybacks and refined Q3 assumption update estimates.
Demand | Margin | Capital Allocation | Innovation & R&D | Regulation Policy | Competitive Dynamics | Guidance Reliability | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 4 | 8 | 1 | 3 | 1 | 1 | |
| 2025Q1 | 4 | 6 | 5 | 1 | 2 | 1 | 4 | |
| 2025Q2 | 12 | 6 | 9 | 4 | 2 | 3 | 3 | 1 |
| 2025Q3 | 9 | 6 | 5 | 2 | 2 | 3 | 5 | |
| 2025Q4 | 8 | 5 | 3 | 1 | 1 | 2 | 1 | 1 |
| 2026Q1 | 6 | 8 | 3 | 3 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 4 | 12 | 9 | 8 | 6 |
| Margin | 4 | 6 | 6 | 6 | 5 | 8 |
| Capital Allocation | 8 | 5 | 9 | 5 | 3 | 3 |
| Innovation & R&D | 1 | 1 | 4 | 2 | 1 | 3 |
| Regulation Policy | 3 | 2 | 2 | 2 | 1 | 1 |
| Competitive Dynamics | 1 | 3 | 3 | 2 | 1 | |
| Guidance Reliability | 1 | 3 | 5 | 1 | ||
| Pricing | 1 | 4 | 1 | 1 |
No 8-K events recorded for this window.
Reported Wednesday, Oct 21. Earnings call pending.
A pre-earnings brief is ready for GL: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
Calendar quarter Q1 2026Earnings call Apr 23, 2026
FY2026 Q1 in brief
Revenue grew 5.4% with operating EPS of $3.43, up 12%, as Globe Life articulated an AI strategy for enterprise-wide margin expansion.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Globe Life (GL), FY2026 Q1: 8/10. Scores: Globe Life’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: GL daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
GAAP revenue YoY +5.35% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Net margin |
|---|---|---|---|---|---|
| FY2024 Q4 | $1.47B | +3.6% | $3.01 | +4.5% | 17.4% |
| FY2025 Q1 | $1.48B | +4.5% | $3.01 | +12.7% | 17.2% |
| FY2025 Q2 | $1.48B | +2.8% | $3.05 | +7.8% | 17.1% |
| FY2025 Q3 | $1.51B | +4.0% | $4.73 | +37.5% | 25.6% |
| FY2025 Q4 | $1.52B | +3.6% | $3.29 | +9.3% | 17.5% |
| FY2026 Q1Selected | $1.56B | +5.3% | $3.39 | +12.6% | 17.3% |
| FY2026 Q2 | $1.60B | +8.0% | $3.65 | +19.7% | 18.0% |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| GLGlobe Life | 8 | +5.3% | AI strategy articulated for enterprise-wide margin expansion | |
| AFLAflac | 6 | +25.0% | Aflac delivered adjusted EPS growth of 6.6% ex-FX to $1.77 as Japan sales surged 25.5% driven by new product momentum and cancer insurance demand, while U.S | |
| METMetLife | 7 | +4.4% | Broad-based adjusted earnings growth across all segments | |
| PRUPrudential Financial | 7 | +6.3% | Retirement segment momentum with record annuity growth |
AI strategy articulated for enterprise-wide margin expansion
Aflac delivered adjusted EPS growth of 6.6% ex-FX to $1.77 as Japan sales surged 25.5% driven by new product momentum and cancer insurance demand, while U.S
Retirement segment momentum with record annuity growth
| Company | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|---|
| GL | 6 | 6 | 6 | 8 | 9 | 8 |
| AFL | 8 | 5 | 5 | 9 | 7 | 6 |
| MET | 6 | 6 | 3 | 8 | 9 | 7 |
| PRU | 7 | 7 | 7 | 7 | 7 | 7 |